LXRX
Price
$1.25
Change
+$0.04 (+3.31%)
Updated
Sep 24, 12:10 PM (EDT)
Capitalization
439.71M
36 days until earnings call
OCUL
Price
$12.69
Change
+$0.44 (+3.59%)
Updated
Sep 24, 12:18 PM (EDT)
Capitalization
2.13B
47 days until earnings call
Interact to see
Advertisement

LXRX vs OCUL

Header iconLXRX vs OCUL Comparison
Open Charts LXRX vs OCULBanner chart's image
Lexicon Pharmaceuticals
Price$1.25
Change+$0.04 (+3.31%)
Volume$4K
Capitalization439.71M
Ocular Therapeutix
Price$12.69
Change+$0.44 (+3.59%)
Volume$1.27K
Capitalization2.13B
LXRX vs OCUL Comparison Chart in %
Loading...
LXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
LXRX vs. OCUL commentary
Sep 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LXRX is a StrongBuy and OCUL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 24, 2025
Stock price -- (LXRX: $1.21 vs. OCUL: $12.25)
Brand notoriety: LXRX and OCUL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: LXRX: 90% vs. OCUL: 92%
Market capitalization -- LXRX: $439.71M vs. OCUL: $2.13B
LXRX [@Biotechnology] is valued at $439.71M. OCUL’s [@Biotechnology] market capitalization is $2.13B. The market cap for tickers in the [@Biotechnology] industry ranges from $97.36B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LXRX’s FA Score shows that 1 FA rating(s) are green whileOCUL’s FA Score has 0 green FA rating(s).

  • LXRX’s FA Score: 1 green, 4 red.
  • OCUL’s FA Score: 0 green, 5 red.
According to our system of comparison, LXRX is a better buy in the long-term than OCUL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LXRX’s TA Score shows that 6 TA indicator(s) are bullish while OCUL’s TA Score has 4 bullish TA indicator(s).

  • LXRX’s TA Score: 6 bullish, 2 bearish.
  • OCUL’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, LXRX is a better buy in the short-term than OCUL.

Price Growth

LXRX (@Biotechnology) experienced а +10.00% price change this week, while OCUL (@Biotechnology) price change was -1.49% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.31%. For the same industry, the average monthly price growth was +10.09%, and the average quarterly price growth was +53.86%.

Reported Earning Dates

LXRX is expected to report earnings on Oct 30, 2025.

OCUL is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (+4.31% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
OCUL($2.13B) has a higher market cap than LXRX($440M). LXRX YTD gains are higher at: 63.846 vs. OCUL (43.443). LXRX has higher annual earnings (EBITDA): -107.44M vs. OCUL (-200.5M). OCUL has more cash in the bank: 391M vs. LXRX (139M). LXRX has less debt than OCUL: LXRX (57M) vs OCUL (76.9M). LXRX (58.4M) and OCUL (56.7M) have equivalent revenues.
LXRXOCULLXRX / OCUL
Capitalization440M2.13B21%
EBITDA-107.44M-200.5M54%
Gain YTD63.84643.443147%
P/E RatioN/AN/A-
Revenue58.4M56.7M103%
Total Cash139M391M36%
Total Debt57M76.9M74%
FUNDAMENTALS RATINGS
LXRX vs OCUL: Fundamental Ratings
LXRX
OCUL
OUTLOOK RATING
1..100
7883
VALUATION
overvalued / fair valued / undervalued
1..100
53
Fair valued
52
Fair valued
PROFIT vs RISK RATING
1..100
10084
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
3741
P/E GROWTH RATING
1..100
19100
SEASONALITY SCORE
1..100
n/a75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OCUL's Valuation (52) in the Pharmaceuticals Other industry is in the same range as LXRX (53) in the Biotechnology industry. This means that OCUL’s stock grew similarly to LXRX’s over the last 12 months.

OCUL's Profit vs Risk Rating (84) in the Pharmaceuticals Other industry is in the same range as LXRX (100) in the Biotechnology industry. This means that OCUL’s stock grew similarly to LXRX’s over the last 12 months.

OCUL's SMR Rating (98) in the Pharmaceuticals Other industry is in the same range as LXRX (98) in the Biotechnology industry. This means that OCUL’s stock grew similarly to LXRX’s over the last 12 months.

LXRX's Price Growth Rating (37) in the Biotechnology industry is in the same range as OCUL (41) in the Pharmaceuticals Other industry. This means that LXRX’s stock grew similarly to OCUL’s over the last 12 months.

LXRX's P/E Growth Rating (19) in the Biotechnology industry is significantly better than the same rating for OCUL (100) in the Pharmaceuticals Other industry. This means that LXRX’s stock grew significantly faster than OCUL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
LXRXOCUL
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
77%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
80%
MACD
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 13 days ago
85%
Bullish Trend 2 days ago
80%
Declines
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 8 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
83%
Aroon
ODDS (%)
N/A
Bullish Trend 2 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
LXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FRIQX12.28N/A
N/A
Fidelity Advisor Real Estate Income M
AFCMX19.24-0.05
-0.26%
American Century Focused Intl Gr R6
MSOIX39.07-0.10
-0.26%
NYLI WMC Enduring Capital Class I
GQSCX14.99-0.06
-0.40%
Glenmede Disciplined US Small Cap Eq Ptf
GSMYX24.67-0.17
-0.68%
Goldman Sachs Small/Mid Cap Growth Instl

LXRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, LXRX has been loosely correlated with PLRX. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if LXRX jumps, then PLRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LXRX
1D Price
Change %
LXRX100%
+4.31%
PLRX - LXRX
39%
Loosely correlated
-2.67%
OCUL - LXRX
37%
Loosely correlated
+0.41%
TECH - LXRX
34%
Loosely correlated
-0.23%
EPIX - LXRX
34%
Loosely correlated
-4.93%
NMRA - LXRX
32%
Poorly correlated
+10.40%
More

OCUL and

Correlation & Price change

A.I.dvisor indicates that over the last year, OCUL has been loosely correlated with EYPT. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if OCUL jumps, then EYPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCUL
1D Price
Change %
OCUL100%
+0.41%
EYPT - OCUL
65%
Loosely correlated
+0.22%
NRIX - OCUL
56%
Loosely correlated
-2.25%
IDYA - OCUL
56%
Loosely correlated
+0.04%
CRNX - OCUL
55%
Loosely correlated
+6.35%
IMVT - OCUL
55%
Loosely correlated
-4.43%
More